Friday March 29, 2024 | Last Update: March 29, 2024 EDT
BioMarin Pharmaceuticals Inc. has announced in a press release that the U.S. Food and Drug Administration (FDA) will be delaying its decision on the company’s new drug application.
Read more >>
BioMarin Pharmaceutical Inc., a manufacturer that primarily makes rare diseases, shelled out $840 million to buy Prosensa Holding NV, an emerging Dutch biopharmaceutical company in an effort to push for approval of drug against muscular dystrophy.
Just In
Most Read
1
2
3
4